Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin 2, and interferon-alpha

G. Groenewegen; A.C. Bloem; G.C. de Gast

Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin 2, and interferon-alpha

Translated title of the contribution: Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin 2, and interferon-alpha

G. Groenewegen, A.C. Bloem, G.C. de Gast

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin 2, and interferon-alpha
Original language	Undefined/Unknown
Journal	Cancer Immunology, Immunotherapy
Volume	51
Publication status	Published - 2002

Cite this

@article{823e5f8808fe43e5af1cb516964bc64d,

title = "Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin 2, and interferon-alpha",

author = "G. Groenewegen and A.C. Bloem and {de Gast}, G.C.",

year = "2002",

language = "Undefined/Unknown",

volume = "51",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin 2, and interferon-alpha. / Groenewegen, G.; Bloem, A.C.; de Gast, G.C.
In: Cancer Immunology, Immunotherapy, Vol. 51, 2002.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin 2, and interferon-alpha

AU - Groenewegen, G.

AU - Bloem, A.C.

AU - de Gast, G.C.

PY - 2002

Y1 - 2002

M3 - Article

SN - 0340-7004

VL - 51

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

ER -